Public Release: 

Early, efficient detection and treatment of rheumatoid arthritis using new

Selective delivery of drugs into inflamed joint tissue may improve tolerability and reduce treatment costs

European League Against Rheumatism

London, United Kingdom, June 8, 2016: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that tiny particles made of a biodegradable polymer (BNPs -- biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects. By coating these particles with a peptide that is only able to target inflamed joint tissue, BNPs may be used to efficiently and selectively deliver drugs and diagnostic probes into arthritic joints.

"Despite dramatic advances in the treatment of RA, currently available therapies can cause several side effects, many patients fail to respond, and true remission is only achieved in a minority," said Dr Paolo Macor lead investigator from the Department of Life Sciences, University of Trieste, Italy. "This is often due to late diagnosis of the pathology," he added.

"There is therefore a need to develop a new tool to enable early diagnosis, and also to develop tissue-specific agents able to reduce systemic side effects. This would increase the potency of the drug with lower doses, and also potentially reduce the cost of treatment," Dr Macor explained.

Unlike conventional drugs, BNPs can be designed to deliver therapeutic agents specifically to the site of inflammation. They also allow investigators to consider or reconsider therapeutic agents that were previously deemed too toxic to deliver through a systemic route. BNPs can also be filled with a contrast agent, such as gadolinium, and then used as a diagnostic tool for an early and functional diagnosis of joint inflammation. Early diagnosis and therapy has been identified as a potentially crucial step in achieving optimal control of disease progression and prognosis in RA.

Using an immunofluorescence technique, these peptide-coated BNPs were shown to preferentially target inflamed joint tissue. A single injection of targeted BNPs loaded with methotrexate completely resolved inflammation in a rat model of antigen-induced arthritis, while the same dose of free-methotrexate injected into the rat's bloodstream was ineffective.

Using a mouse model of chronic collagen-induced arthritis, an equivalent therapeutic effect was obtained comparing methotrexate-loaded BNPs and the same dose of free methotrexate with no toxic effects.

"The advantage of being able to deliver methotrexate in this targeted way is to be able to gain the benefits from this key treatment of RA, while reducing the risk of adverse effects that are more frequent at high doses," concluded Dr Macor.

Abstract Number: OP0023

###

NOTES TO EDITORS:

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress

Press Office in the London Suite at ExCel London during EULAR 2016 or on: Email: eularpressoffice@cohnwolfe.com

Onsite tel: 44-0-7725-915-492 / 44-0-7786-171-476

Twitter: @EULAR_Press

Youtube: Eular Pressoffice

About EULAR

The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with Rheumatic Musculoskeletal Diseases (RMD) throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of RMD and the rehabilitation of those it affects.

EULAR underlines the importance of combating rheumatic diseases not only by medical means, but also through a wider context of care for rheumatic patients and a thorough understanding of their social and other needs. EULAR is supported in this mission by its 45 scientific member societies, 36 PARE (People with Arthritis/Rheumatism in Europe) organisations, 22 HPR (Health Professionals in Rheumatology) associations and 23 corporate members.

The EULAR Annual European Congress of Rheumatology is the foremost international medical meeting announcing the latest research on rheumatic and musculoskeletal diseases. EULAR 2016 is

expected to attract over 14,000 delegates from around 120 countries. Most if not all professions working in the vast field of RMD will be represented.

To find out more about the activities of EULAR, visit: http://www.eular.org

References

1. EULAR 2016; London: Abstract OP0023

2. Pham CTN. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 2011; 3(6): 607-619

3. Macor P. Development of nanoparticles specific for inflamed synovial tissue. http://dsv.units.it/en/research/researchareas/researchgroups/18231 [Accessed 27 April 2016]

4. Nell V, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906-14

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.